Tessera Therapeutics
Jonathan Weissman is the Landon T. Clay professor of Biology at Whitehead Institute for Biomedical Research and the Department of Biology at MIT, and an investigator of the Howard Hughes Medical Institute.
He serves as the co-director of the Innovative Genomics Institute (IGI) of Berkeley and UCSF and on the President’s Advisory Group for the Chan Zuckerberg Biohub. He also is the chairman of the scientific advisory board for the Stowers Institute and serves on the scientific advisory board for Amgen and the Helen Hay Whitney Foundation. Additionally, Jonathan is a co-founder of KSQ therapeutics and Maze therapeutics.
He has received the Ira Herskowitz Award from the Genetic Society of America, Irving Sigal Young Investigator Award from the Protein Society, the Raymond and Beverly Sackler International Prize in Biophysics, the National Academy of Sciences Award for Scientific Discovery, and the Keith R. Porter Lecture Award from the American Society for Cell Biology. Jonathan is a member of the National Academy of Sciences.
This person is not in the org chart
This person is not in any offices
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.